GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO) » Definitions » Financial Strength

BIO (Bio-Rad Laboratories) Financial Strength : 7 (As of Sep. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Bio-Rad Laboratories Financial Strength?

Bio-Rad Laboratories has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Bio-Rad Laboratories's Interest Coverage for the quarter that ended in Sep. 2024 was 5.30. Bio-Rad Laboratories's debt to revenue ratio for the quarter that ended in Sep. 2024 was 0.46. As of today, Bio-Rad Laboratories's Altman Z-Score is 3.00.


Competitive Comparison of Bio-Rad Laboratories's Financial Strength

For the Medical Devices subindustry, Bio-Rad Laboratories's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Financial Strength distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Financial Strength falls into.



Bio-Rad Laboratories Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Bio-Rad Laboratories's Interest Expense for the months ended in Sep. 2024 was $-12 Mil. Its Operating Income for the months ended in Sep. 2024 was $64 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1,200 Mil.

Bio-Rad Laboratories's Interest Coverage for the quarter that ended in Sep. 2024 is

Interest Coverage=-1*Operating Income (Q: Sep. 2024 )/Interest Expense (Q: Sep. 2024 )
=-1*64.466/-12.174
=5.30

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Bio-Rad Laboratories's Debt to Revenue Ratio for the quarter that ended in Sep. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.262 + 1200.062) / 2598.916
=0.46

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Bio-Rad Laboratories has a Z-score of 3.00, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 3 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Rad Laboratories  (NYSE:BIO) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Bio-Rad Laboratories has the Financial Strength Rank of 7.


Bio-Rad Laboratories Financial Strength Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Rad Laboratories Business Description

Traded in Other Exchanges
Address
1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Executives
Tania Devilliers officer: INT PRIN ACCTG OFC C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Sedat Evran officer: EVP, Global Supply Chain C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Corey Colleen officer: EVP, Global Human Resources 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Diane Dahowski officer: EVP, Global Supply Chain C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Schwartz Allison director C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Simon May officer: EVP, President, LSG C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew J. Last officer: EVP, Chief Operating Officer 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Ajit Ramalingam officer: SVP, Chief Accounting Officer C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Ilan Daskal officer: EVP, Chief Financial Officer 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Timothy S Ernst officer: EVP, General Counsel & Sec 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Dara Wright officer: Executive Vice President C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Michael Crowley officer: EVP, GBL Commercial Operations 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Steven D Schwartz 10 percent owner 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice N Schwartz director, 10 percent owner
Norman D Schwartz director, 10 percent owner, officer: Chairman, President, and CEO 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547